Percutaneos radiofrequency (RF) ablation of osteoid osteoma has been proved as an effective treatment. However, there is limited data regarding other tumors. It also has been described in the treatment of other benign and malignant tumors like chondroblastoma and metastasis. In fact, one of the reported cases of chondroblastoma that were treated with RF was radiological small lesion erroneously diagnosed prior to treatment as osteoid osteomas. It was diagnosed as chondroblastoma only retrospectively. The aim of this study is to describe the success of RF as a definitive treatment and as an alternative to traditional surgery for the treatment of large chondroblastoma and chondromyxoid-fibroma which were diagnosed as such prior to ablation. From April 2006 to April 2007, 3 patients with chondroblastoma and 1 patient with chondromyxoid-fibroma were treated with RF ablation using cool-tip probe. Three procedures were done in the CT suit and one in the operating room. There were 3 girls and 1 boy. Mean age was 12 y 9 m (range 11 y 6 m – 14 y 6 m). Clinical and radiological follow-up was performed to assess outcome. The mean follow-up was 23.25 months (range 20–32 months). Three patients healed after single treatment and one needed repeated treatment. No immediate or delayed complications were observed. Follow up MRI showed no enhancement in the lesion and an extra-lesional sclerotic ream signifying RF effect beyond the lesion area. All patients returned to complete normal painless function. In spite of the small number of patients, percutaneous RF ablation was shown to be an effective and safe minimally invasive procedure for the treatment of chondroblastoma and chondromyxoid-fibroma, avoiding the morbidity of commonly used wide excision surgeries.
Radiofrequency (RF) ablation carries success rate of 70–90% in the treatment of Osteoid Osteoma (OO). Failures are related to incomplete ablation which might be caused by the probe’s small heating radius (0.5–0.8 cm). Water cooled tips were developed in order to prevent charring of the tip and adjacent tissues and to allow for a larger, up to 3cm ablation diameter. To our knowledge safety and efficiency of this probe in the treatment of pediatric OO were never reported. Our goal was to examine if this technique, when added to conventional RF ablation, improves the clinical results and whether it carries any additional risks in the pediatric population. Twenty two OO patients, 15 males and 7 females, 3 years and 6 months to 18 years old, were treated using the Cool-tip™ Tyco probe in a cooled mode followed immediately by conventional RF cycle under general anesthesia, in the CT suite. Fifteen of the lesions were in the femur, 2 in the tibia and the remainder lesions were located in the humerus, talus, calcaneus, 2nd metatarsus and sacrum. The OO was intraarticular in 5 patients: femur (3), calcaneus and Talus. Follow-up period averaged 38.5 months (range 16–66 months). All patients but one had their symptoms resolved immediately following a single treatment (95.5% success rate). One patient had partial relief and underwent second successful ablation. There were one recurrence after 18 months and one superficial infection. No fractures, neurovascular complications or growth disturbances were encountered. We conclude that the addition of a Cool-tip cycle to conventional RF ablation in children is safe, efficient and reduces the risk of recurrence without adverse effects specific to this age group. We attribute this success to the larger diameter of heat distribution occurring due to cooling of the tip and the prevention of probe and tissue charring.
The system was utilized as well in all cases for choosing the nail point of entry, in 7 (25%) for blocking screws planning and in 4 (16%) for nail locking successfully.
The infection rate for the entire group was 12%. Non-union occurred in 8%. Secondary amputation rate was 4%
The morphological structure of the collagen, namely, the architectural structure of the material and single fibers, as shown by the SEM in various magnifications (100, 1200, 2500 and 5000), was much more similar when comparing between the control group and the microwave group than in the autoclave processed group.
Mesenchymal Stem Cells (MSCs) are key regulators in senile osteoporosis and in bone formation and regeneration. MSCs are therefore suitable candidates for stem cells mediated gene therapy of bone. Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) is a highly osteoinductive cytokine, promoting osteogenic differentiation of MSCs. We hypothesized that genetically engineered MSCs, expressing rhBMP2, can be utilized for targeted cell mediated gene therapy for local and systemic bone disorders and for bone/cartilage tissue engineering. Engineered MSCs expressing rhBMP-2 have both autocrine and paracrine effects enabling the engineered cells to actively participate in bone formation. We conditionally expressed rhBMP2 (tet-controlled gene expression, tet-off system) in mouse and human mesenchymal stem cells. RhBMP2 expressing clones (tet-off and adeno-BMP2 infected MSCs), spontaneously differentiated into osteogenic cells in vitro and in vivo. Engineered MSCs were transplanted locally and tracked in vivo in radial segmental defects (regenerating site) and in ectopic muscular and subcutaneous sites (non-regenerating sites). In vitro and in vivo analysis revealed rhBMP2 expression and function, confirmed by RT-PCR, ELISA, western blot, immunohistochemistry and bioassays. Secretion of rhBMP2 in vitro was controlled by tetracycline and resulted in secretion of 1231 ng/24 hours/106 cells. Quantitative Micro-CT 3-Dimentional reconstruction revealed complete bone regeneration regulated by tetracycline in vivo, indicating the potential of this platform for bone and cartilage tissue engineering. Angiogenesis, a crucial element in tissue engineering, was increased by 10-folds in transplants of rhBMP2 expressing MSCs (tet-off), shown by histomorphometry and MRI analysis (p<
0.05). In order to establish a gene therapy platform for systemic bone disorders, MSCs with tet-controlled rhBMP-2 expression, were injected systemically (iv). These engineered MSCs were genetically modified in order to achieve homing to the bone marrow. Systemic non invasive tracking of engineered MSCs was achieved by recording topographical bioluminescence derived from luciferase expression detected by a coupled charged CCD imaging camera. For clinical situations that require immuno-isolation of transplanted cells, we developed an additional platform utilizing cell encapsulation technique. Immuno-isolated engineered MSCs, with tet-controlled rhBMP-2 expression, encapsulated with sodium alginate induced bone formation by paracrine effect of secreted rhBMP-2. Finally, we have characterized a novel tissue-engineering platform composed of engineered MSCs and biodegradable polymeric scaffolds, creating a 3D bone tissue in rotating Bioreactors. Our results indicate that engineered MSCs and polymeric scaffolds can be utilized for ex vivo bone tissue engineering. We therefore conclude that genetically engineered MSCs expressing rhBMP-2 under tetracycline control are applicable for: a) local and systemic gene therapy to bone, and b) bone tissue engineering. Our studies should lead to the creation of gene therapy platforms for systemic and local bone diseases in humans and bone/cartilage tissue engineering.